If you’ve been diagnosed with both PCOS and endometriosis, you’ve probably been managed for each one separately, with different specialists, different treatment approaches, and no one connecting the thread between them. The gynecologist addresses the endometriosis. The reproductive endocrinologist addresses the PCOS. Each condition gets its own management plan, and the question of why both showed up in the same body at the same time rarely gets asked, let alone answered.
That question matters more than most women are told. PCOS and endometriosis are not simply two separate conditions that happen to co-occur by coincidence in some women. They share underlying drivers involving immune dysregulation, hormonal imbalance, inflammatory burden, and gut health dysfunction that produce both conditions simultaneously in susceptible individuals. Understanding those shared drivers is what makes it possible to address both conditions more comprehensively than managing each one in isolation ever could.
The co-occurrence of PCOS and endometriosis is more frequent than the research has historically suggested, partly because both conditions are significantly underdiagnosed individually and the overlap has therefore been underestimated. According to a systematic review published in the European Journal of Obstetrics and Gynecology and Reproductive Biology, the prevalence of endometriosis in women with PCOS is meaningfully higher than in the general population, and several studies have identified rates of co-occurrence that challenge the traditional view of these conditions as having distinct and non-overlapping patient populations.
Part of the diagnostic challenge is that PCOS and endometriosis can produce overlapping symptoms that complicate the clinical picture. Both conditions cause pelvic pain and menstrual irregularities. Both are associated with fertility challenges. Both produce hormonal symptoms that affect mood, energy, and quality of life in ways that are difficult to attribute to one condition versus the other without thorough evaluation. When the symptom picture is complex and overlapping, the tendency in conventional care is to identify and manage the more obvious diagnosis without fully investigating whether a second condition is also present.
The clinical implication is significant. A woman being managed for PCOS alone who also has endometriosis is receiving care for half her picture. The inflammatory and immune drivers of endometriosis that aren’t being addressed continue to affect her hormonal health, her pain picture, her fertility, and her systemic inflammatory burden in ways that no PCOS management protocol will resolve.
Polycystic ovarian syndrome is a hormonal and metabolic disorder characterized by elevated androgens, irregular or absent ovulation, and often the presence of multiple small follicles on the ovaries. The name is somewhat misleading because cysts aren’t required for the diagnosis, and many women with the hormonal and metabolic pattern of PCOS don’t have obvious cysts on imaging.
What most women with PCOS aren’t told is that PCOS is not a single condition with a single cause. It’s a syndrome, meaning it describes a cluster of findings that can result from several different underlying drivers. The most common drivers include insulin resistance, which elevates insulin levels and drives excess androgen production from the ovaries. Adrenal dysfunction, where elevated adrenal androgens rather than ovarian androgens are the primary driver, producing a distinct presentation that responds poorly to insulin-sensitizing approaches. Chronic systemic inflammation, which directly stimulates ovarian androgen production and impairs insulin receptor function simultaneously. And thyroid dysfunction, which alters sex hormone binding globulin levels and disrupts the HPO axis communication that governs ovulation.
According to research published in the Journal of Clinical Endocrinology and Metabolism, insulin resistance is present in approximately 65 to 70% of women with PCOS regardless of body weight, making it the most prevalent driver but not a universal one. Understanding which driver or combination of drivers is primary in a given patient determines which interventions will actually be effective, and applying the same management approach to all PCOS patients regardless of their specific driver picture is one of the primary reasons PCOS management produces such inconsistent outcomes across individuals.
Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic tissue, and in some cases on the bowel or bladder. This tissue responds to hormonal signals just as uterine lining does, thickening, breaking down, and bleeding with each menstrual cycle, but with no way to exit the body, creating trapped inflammation, scarring, and adhesion formation that distorts pelvic anatomy and drives the chronic pain and fertility challenges that characterize the condition.
What makes endometriosis particularly important to understand from a root cause perspective is its immune dimension. In women without endometriosis, the immune system clears retrograde menstrual flow, the blood and endometrial tissue that flows backward through the fallopian tubes into the pelvic cavity, before it can implant and grow. In women with endometriosis, immune surveillance in the pelvic environment is specifically impaired in ways that allow this tissue to establish itself, develop its own blood supply, and grow outside the uterus.
According to research published in Human Reproduction Update, this immune dysfunction is not limited to the pelvis. Women with endometriosis have measurably different systemic immune profiles compared to women without the condition, with elevated inflammatory cytokines, altered natural killer cell activity, and increased autoimmune reactivity that reflects a systemic immune environment rather than a localized pelvic problem. This systemic immune picture is one of the most important connections between endometriosis and PCOS, because many of the same immune drivers are relevant to both conditions.
Understanding why PCOS and endometriosis co-occur at higher than expected rates requires understanding the physiological ground they share. Several underlying drivers are relevant to both conditions simultaneously, which explains both the co-occurrence pattern and why addressing those shared drivers is more effective than managing each condition in isolation.
Systemic inflammation is the most consistent shared driver. Chronic low-grade inflammation directly stimulates androgen production in the ovaries, impairs insulin receptor function, drives the immune dysregulation that allows endometriotic tissue to implant and grow, and creates the systemic inflammatory environment that sustains both conditions simultaneously. According to research published in Fertility and Sterility, women with both PCOS and endometriosis have measurably higher systemic inflammatory markers than women with either condition alone, suggesting a compounding inflammatory burden that requires targeted evaluation and intervention.
Gut health dysfunction is central to both conditions through mechanisms that are increasingly well characterized in the research. The gut microbiome influences estrogen metabolism through the estrobolome, the collection of gut bacteria that regulate estrogen clearance and recirculation. When the estrobolome is imbalanced through gut dysbiosis, estrogen that should be cleared through the bowel gets reactivated and recirculated, contributing to the estrogen dominance patterns that drive endometriosis growth and the hormonal imbalances relevant to PCOS. Intestinal permeability drives systemic immune activation that contributes to both the androgen-stimulating inflammation of PCOS and the impaired pelvic immune surveillance of endometriosis. According to a review published in the Journal of Clinical Medicine, gut microbiome dysbiosis is found at significantly higher rates in women with both PCOS and endometriosis compared to healthy controls, and the specific microbiome alterations identified overlap substantially between the two conditions.
HPA axis dysregulation and chronic stress affect both conditions through cortisol’s effects on insulin sensitivity, androgen production, immune regulation, and estrogen metabolism. Cortisol directly antagonizes insulin action, worsening the insulin resistance central to most PCOS presentations. It also impairs the immune surveillance function relevant to endometriosis by altering natural killer cell activity in ways that reduce clearance of retrograde menstrual flow. For women managing both conditions in the context of lives that are already stressful, this physiological dimension of the stress burden is clinically significant and frequently unaddressed.
Thyroid dysfunction is more common in women with both PCOS and endometriosis than in the general population, and it contributes to both conditions through its effects on sex hormone binding globulin, insulin sensitivity, immune regulation, and inflammatory burden. According to research published in Thyroid, Hashimoto’s thyroiditis co-occurs with PCOS at significantly higher rates than chance would predict, and the autoimmune inflammation of active Hashimoto’s contributes to the systemic inflammatory environment that drives both conditions. Missing an underlying thyroid or autoimmune thyroid condition in a woman with PCOS and endometriosis is one of the most common reasons her care produces incomplete results.
The conventional approach to PCOS and endometriosis when they co-occur is to manage each one through its own standard treatment pathway. Hormonal suppression for endometriosis through birth control, hormonal IUDs, or GnRH agonists. Insulin sensitization or hormonal management for PCOS. Each intervention may produce some improvement in its target condition while doing nothing about the shared drivers sustaining both.
The fundamental problem is that treating the downstream hormonal manifestations of both conditions without addressing the upstream immune, inflammatory, gut, and metabolic drivers that sustain them produces temporary management rather than meaningful resolution. When birth control is discontinued, the endometriosis drivers are still active. When the PCOS medication is stopped, the underlying insulin resistance and inflammatory picture is still there. The conditions don’t resolve because the conditions were never the target of the treatment.
A root cause approach asks a different set of questions. What is driving the systemic inflammation active in this patient, and what is sustaining it? What is the state of gut health and the estrobolome, and how is that affecting estrogen metabolism relevant to both conditions? What is the thyroid picture, and is there autoimmune activity contributing to the immune dysregulation? What is the specific PCOS driver picture, insulin resistance, adrenal, inflammatory, or a combination, and what does that mean for how the hormonal picture should be supported? What is the HPA axis pattern, and how is cortisol affecting insulin sensitivity, immune function, and estrogen metabolism simultaneously?
These questions, and the thorough evaluation required to answer them, are what make it possible to build a care plan that addresses both conditions from a shared root rather than managing each one separately in perpetuity.
At True Health Clinic, an evaluation for a woman presenting with PCOS, endometriosis, or both conditions begins with a thorough history that covers the full timeline of symptoms for each condition, how the hormonal picture has evolved over time, what treatments have been tried and what they produced, what the menstrual cycle pattern looks like in detail, what the pain picture involves and how it tracks with the cycle, what gut health and digestive function have been like, and what the full clinical picture looks like across all systems.
The testing order reflects what the history and clinical picture suggest is most relevant for that individual. Comprehensive hormone evaluation that captures the full picture of estrogen metabolism, progesterone status, androgen levels, and adrenal output. A complete thyroid panel with antibody testing that evaluates both thyroid function and autoimmune thyroid activity. Gut health assessment that evaluates the microbiome and gut barrier integrity relevant to estrogen metabolism and systemic immune function. Metabolic markers including fasting insulin that evaluate the insulin resistance dimension central to most PCOS presentations. Inflammatory markers that capture the systemic inflammatory burden driving both conditions.
The care plan built from that evaluation addresses the specific combination of shared drivers identified in that individual’s case, sequenced in a logical order that produces cumulative improvement rather than partial management of each condition in isolation.
For women in Wichita, Hesston, and the surrounding areas of Kansas who have been managing PCOS, endometriosis, or both without feeling like the care has gone deep enough into what’s actually driving their conditions, a free 15-minute phone consultation with Dr. Skidmore is the starting point for a different kind of conversation.
Book Your Free 15-Minute Consultation
Note: This article is intended for educational purposes and should not be used to diagnose or treat any medical condition. If you’re experiencing symptoms discussed in this article, consult a qualified healthcare professional for personalized guidance.
| PHOTOGRAPHY BY lauragonzalezphotography.com | Made by a Peanut |